BACE1 and Alzheimer disease: The “amyloid cascade” hypothesis for AD, the most prevalent age-related dementia affecting currently more than 24 million patients worldwide24, states that an imbalance between formation and elimination of Aβ peptide is the initial event in the pathogenesis of AD25, marking BACE1 a promising drug target to prevent the generation of Aβ peptides26.